MA39164B1 - Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine - Google Patents

Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine

Info

Publication number
MA39164B1
MA39164B1 MA39164A MA39164A MA39164B1 MA 39164 B1 MA39164 B1 MA 39164B1 MA 39164 A MA39164 A MA 39164A MA 39164 A MA39164 A MA 39164A MA 39164 B1 MA39164 B1 MA 39164B1
Authority
MA
Morocco
Prior art keywords
methylpyrrolidin
methanone
triazol
imidazol
benzo
Prior art date
Application number
MA39164A
Other languages
English (en)
Other versions
MA39164A1 (fr
Inventor
Christoph Boss
Christine Brotschi
Bibia Heidmann
Thierry Sifferlen
Jodi T Williams
Markus Gude
Raumer Markus Von
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MA39164A1 publication Critical patent/MA39164A1/fr
Publication of MA39164B1 publication Critical patent/MA39164B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline de chlorhydrate de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone, des procédés de préparation associés, des compositions pharmaceutiques contenant ladite forme cristalline et son utilisation comme médicament, particulièrement comme antagoniste des récepteurs à l'oréxine.
MA39164A 2013-12-03 2014-12-02 Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine MA39164B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2013060595 2013-12-03
PCT/IB2014/066509 WO2015083071A1 (fr) 2013-12-03 2014-12-02 Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine

Publications (2)

Publication Number Publication Date
MA39164A1 MA39164A1 (fr) 2017-08-31
MA39164B1 true MA39164B1 (fr) 2019-03-29

Family

ID=52282787

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39164A MA39164B1 (fr) 2013-12-03 2014-12-02 Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine

Country Status (32)

Country Link
US (2) US9790208B2 (fr)
EP (1) EP3077390B1 (fr)
JP (1) JP6091716B2 (fr)
KR (1) KR101839716B1 (fr)
CN (1) CN105793258B (fr)
AU (1) AU2014358743B2 (fr)
CA (1) CA2929720C (fr)
CL (1) CL2016001348A1 (fr)
CY (1) CY1119687T1 (fr)
DK (1) DK3077390T3 (fr)
EA (1) EA030109B1 (fr)
ES (1) ES2651508T3 (fr)
HK (1) HK1225736B (fr)
HR (1) HRP20171772T1 (fr)
HU (1) HUE034656T2 (fr)
IL (1) IL245922B (fr)
LT (1) LT3077390T (fr)
MA (1) MA39164B1 (fr)
MX (1) MX362701B (fr)
MY (1) MY176244A (fr)
NO (1) NO3077390T3 (fr)
NZ (1) NZ721493A (fr)
PH (1) PH12016500989A1 (fr)
PL (1) PL3077390T3 (fr)
PT (1) PT3077390T (fr)
SA (1) SA516371248B1 (fr)
SG (1) SG11201604541WA (fr)
SI (1) SI3077390T1 (fr)
TW (1) TWI636982B (fr)
UA (1) UA119151C2 (fr)
WO (1) WO2015083071A1 (fr)
ZA (1) ZA201604501B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334544B (zh) 2012-06-04 2016-10-19 埃科特莱茵药品有限公司 苯并咪唑脯氨酸衍生物
TWI664177B (zh) 2013-12-03 2019-07-01 瑞士商愛杜西亞製藥有限公司 晶形
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
TWI756418B (zh) 2017-05-03 2022-03-01 瑞士商愛杜西亞製藥有限公司 2-([1,2,3]三唑-2-基)-苯甲酸衍生物之製備
BR112022020924A2 (pt) 2020-04-19 2023-02-14 Idorsia Pharmaceuticals Ltd Métodos de tratamento de um transtorno do sono, a sonolência diurna em um indivíduo, a insônia, e, daridorexante na forma de sal livre ou farmaceuticamente aceitável
CN115925699B (zh) * 2022-02-25 2023-10-03 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途
CN117736193A (zh) * 2023-12-19 2024-03-22 南京知和医药科技有限公司 一种氘代稠环化合物及其制备方法与用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
EP1289955B1 (fr) 2000-06-16 2005-04-13 Smithkline Beecham Plc Piperidines utiles en tant qu'antagonistes du recepteur d'orexine
CA2425185A1 (fr) 2000-10-06 2002-04-11 Stephane De Lombaert Derives de benzimidazole et d'indole en tant que modulateurs des recepteurs de la corticoliberine
WO2002044172A1 (fr) 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Derives de la morpholine utilises comme antagonistes des recepteurs de l'orexine
EP1435955A2 (fr) 2001-05-05 2004-07-14 SmithKline Beecham P.L.C. Derives d'amines cycliques n-aroyl utilises comme antagonistes du recepteur d'orexine
EP1956020A3 (fr) 2001-05-05 2008-08-20 Smithkline Beecham Plc Dérivés 1-[2-(hétérocyclyl-aminométhyl)-pipéridin-1-YL]-1-(2-méthyl-5-phényl-hétérocyclyl)- méthanone et composés similaires en tant que antagonists oréxin-1 pour le traitement de la obesité
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
ES2266549T3 (es) * 2001-06-28 2007-03-01 Smithkline Beecham Plc Derivados de n-aroil-amina ciclicos como antagonistas del receptor de orexina.
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
JP2006504695A (ja) 2002-09-18 2006-02-09 グラクソ　グループ　リミテッド オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
NZ550216A (en) 2004-03-01 2009-08-28 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
EA015256B1 (ru) 2006-03-15 2011-06-30 Актелион Фармасьютикалз Лтд. Производные тетрагидроизохинолина для повышения функции памяти
WO2007135527A2 (fr) * 2006-05-23 2007-11-29 Pfizer Products Inc. Composés de benzimidazolyle
EP2069332B1 (fr) 2006-08-15 2011-03-02 Actelion Pharmaceuticals Ltd. Composés d'azétidine en tant qu'antagonistes du recepteur orexin
ES2350460T3 (es) 2006-09-29 2011-01-24 Actelion Pharmaceuticals Ltd. Derivados de 3-aza-biciclo[3.1.0]hexano.
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
WO2008087611A2 (fr) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Dérivés de pyrrolidine et de piperidine
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
DE602008002934D1 (de) 2007-05-14 2010-11-18 Actelion Pharmaceuticals Ltd 2-cyclopropylthiazolderivate
CA2687230A1 (fr) 2007-05-23 2008-12-11 Merck & Co., Inc. Antagonistes du recepteur de la cyclopropylpyrrolidine orexine
JP2010531871A (ja) 2007-07-03 2010-09-30 アクテリオン ファーマシューティカルズ リミテッド ３−アザ−ビシクロ［３．３．０］オクタン化合物
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
CN101796053A (zh) 2007-07-03 2010-08-04 葛兰素集团有限公司 用作食欲素受体拮抗剂的哌啶衍生物
TW200904799A (en) 2007-07-27 2009-02-01 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
BRPI0814593A2 (pt) 2007-07-27 2015-01-20 Actelion Pharmaceuticals Ltd Composto, composição farmacêutica que o contém e uso do composto.
EP2207778A2 (fr) 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines et pipéridines en tant qu'antagonistes du récepteur de l'orexine
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
JP2011512400A (ja) 2008-02-21 2011-04-21 アクテリオン ファーマシューティカルズ リミテッド ２−アザ−ビシクロ［２．２．１］ヘプタン誘導体
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CN102083827A (zh) 2008-07-07 2011-06-01 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的噻唑烷化合物
WO2010038200A1 (fr) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Composés d'oxazolidine utilisables en tant qu'antagonistes des récepteurs à orexine
WO2010060470A1 (fr) 2008-11-26 2010-06-03 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine
WO2010060471A1 (fr) 2008-11-26 2010-06-03 Glaxo Group Limited Dérivés de la pipéridine utiles en tant qu’antagonistes du récepteur de l’orexine
EP2358713A1 (fr) 2008-11-26 2011-08-24 Glaxo Group Limited Dérivés de l imidazopyridazine agissant en tant qu antagonistes de l orexine
KR20110091582A (ko) 2008-12-02 2011-08-11 글락소 그룹 리미티드 Ｎ-｛［1ｒ,4ｓ,6ｒ-3-(2-피리디닐카르보닐)-3-아자비시클로［4.1.0］헵트-4-일］메틸｝-2-헤테로아릴아민 유도체 및 그의 용도
CA2745420A1 (fr) 2008-12-02 2010-06-10 Glaxo Group Limited Derives de n-{[(1s,4s,6s)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-heteroarylamine et leurs utilisations
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
JP2012524760A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド オレキシンアンタゴニストとして使用される３−アザビシクロ［４．１．０］ヘプタン
CN103079563B (zh) 2010-08-24 2015-07-08 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的脯氨酸磺酰胺衍生物
CA2815179A1 (fr) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Derives de lactame utiles en tant qu'antagonistes du recepteur de l'orexine
EP2675801B1 (fr) 2011-02-18 2015-04-08 Actelion Pharmaceuticals Ltd. Nouveaux dérivés de pyrazole et d'imidazole utiles à titre d'antagonistes d'orexine
SG11201401665WA (en) 2011-11-08 2014-09-26 Actelion Pharmaceuticals Ltd 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists
DK2838900T3 (da) 2012-04-17 2019-10-14 Gilead Sciences Inc Forbindelser og fremgangsmåder til antiviral behandling
CN104334544B (zh) 2012-06-04 2016-10-19 埃科特莱茵药品有限公司 苯并咪唑脯氨酸衍生物
EA201500399A1 (ru) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
CA2902135A1 (fr) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Derives d'amide d'azetidine en tant qu'antagonistes des recepteurs d'orexine
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
TWI664177B (zh) 2013-12-03 2019-07-01 瑞士商愛杜西亞製藥有限公司 晶形
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну

Also Published As

Publication number Publication date
ES2651508T3 (es) 2018-01-26
BR112016012625A2 (fr) 2017-08-22
ZA201604501B (en) 2018-12-19
CA2929720A1 (fr) 2015-06-11
PT3077390T (pt) 2017-12-15
CA2929720C (fr) 2019-06-18
IL245922A0 (en) 2016-08-02
BR112016012625A8 (pt) 2017-12-26
TWI636982B (zh) 2018-10-01
EA201600436A1 (ru) 2016-11-30
MY176244A (en) 2020-07-24
PL3077390T3 (pl) 2018-02-28
PH12016500989B1 (en) 2016-06-20
IL245922B (en) 2019-10-31
HK1225736B (zh) 2017-09-15
EP3077390A1 (fr) 2016-10-12
EA030109B1 (ru) 2018-06-29
MX362701B (es) 2019-02-01
CL2016001348A1 (es) 2016-11-25
MA39164A1 (fr) 2017-08-31
US20160355506A1 (en) 2016-12-08
EP3077390B1 (fr) 2017-09-13
LT3077390T (lt) 2017-11-27
US20180002317A1 (en) 2018-01-04
US10023560B2 (en) 2018-07-17
PH12016500989A1 (en) 2016-06-20
WO2015083071A1 (fr) 2015-06-11
NO3077390T3 (fr) 2018-02-10
JP2016539135A (ja) 2016-12-15
HUE034656T2 (hu) 2018-02-28
AU2014358743B2 (en) 2018-11-29
SA516371248B1 (ar) 2018-03-19
MX2016007216A (es) 2016-09-07
DK3077390T3 (da) 2017-11-06
AU2014358743A1 (en) 2016-07-14
SI3077390T1 (sl) 2017-12-29
HRP20171772T1 (hr) 2017-12-29
CY1119687T1 (el) 2018-04-04
JP6091716B2 (ja) 2017-03-08
UA119151C2 (uk) 2019-05-10
NZ721493A (en) 2021-12-24
SG11201604541WA (en) 2016-07-28
CN105793258A (zh) 2016-07-20
CN105793258B (zh) 2018-12-28
TW201605839A (zh) 2016-02-16
US9790208B2 (en) 2017-10-17
KR20160093683A (ko) 2016-08-08
KR101839716B1 (ko) 2018-03-16

Similar Documents

Publication Publication Date Title
MA39164B1 (fr) Forme de sel cristalline de (s)-(2-(6-chloro-7-méthyl-1 h-benzo[d]imidazol- 2-yl)-2-méthylpyrrolidin-1-yl)(5-méthoxy-2-(2h-1,2,3-triazol-2-yl)phényl)méthanone comme antagoniste des récepteurs à l'oréxine
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
MA39163A1 (fr) Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
UA100877C2 (ru) Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
PH12017501424B1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MA35107B1 (fr) Composition pharmaceutique antihypertensive
PE20151535A1 (es) Derivado de dihidropiridazin-3,5-diona
IN2015DN00538A (fr)
EA201692220A1 (ru) Твердые формы противовирусного соединения
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора
MA32224B1 (fr) Derives de (pyrazolyl-carbonyl) imidazolidinone pour le traitement de maladies retrovirales
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
MA50899B1 (fr) Composés utiles pour l'inhibition de cdk7
TR201719911A2 (tr) Raloksi̇fen ve en az bi̇r anti̇psi̇koti̇k ajan i̇çeren kompozi̇syon
UA101367C2 (en) Normal;heading 1;heading 2;heading 3;HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS